We are live on ! Find out more
QTTB icon

Q32 Bio

50 hedge funds and large institutions have $455M invested in Q32 Bio in 2018 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 24 increasing their positions, 7 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

243% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 7

9% more capital invested

Capital invested by funds: $419M → $455M (+$36.8M)

0.09% less ownership

Funds ownership: 3.06%2.97% (-0.09%)

6% less funds holding

Funds holding: 5350 (-3)

30% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 10

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
50
Holders Change
-3
Holders Change %
-5.66%
% of All Funds
1.14%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
7
Increased
24
Reduced
7
Closed
10
Calls
Puts
Net Calls
Net Calls Change

QTTB Hedge Fund Activity: Q3 2018 in Review

50 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Q32 Bio (QTTB) for Q3 2018, worth a combined $455M — up 8.8% from $419M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of QTTB and 7 opened new positions — a net loss of 3 holders — while 7 trimmed existing stakes and 24 added.

The largest buyer was JP Morgan Chase, adding an estimated $9.74M. The largest seller was Fidelity Investments, cutting an estimated $19M.

  • 50 institutional investors held Q32 Bio (QTTB) as of Q3 2018, down from 53 in Q2 2018.
  • Funds reported $455M of Q32 Bio stock for Q3 2018, up 8.8% quarter-over-quarter.
  • 7 funds opened new Q32 Bio positions in Q3 2018 and 10 closed out, a net change of -3 holders.
  • The largest Q32 Bio buyer in Q3 2018 was JP Morgan Chase, an estimated $9.74M added.
  • The largest Q32 Bio seller in Q3 2018 was Fidelity Investments, an estimated $19M sold.

Based on aggregated 13F filings for Q3 2018.